BioMatrix Infusion Pharmacy, backed by private equity firm Frazier Healthcare Partners, announced the successful acquisition of LUX Infusion, effective October 17, 2025. With this acquisition, BioMatrix extends its reach into the Pacific Northwest. Financial terms of the deal were not disclosed.
LUX Infusion is Alaska’s leading independent ambulatory infusion provider, offering safe, convenient and cost-effective care for patients with acute and chronic conditions. The company has three locations across the state.
Headquartered in Plantation, Florida, BioMatrix Infusion Pharmacy is a nationwide, independent specialty infusion pharmacy. Frazier Healthcare Partners acquired the company in June 2024.
“Our decision to acquire LUX Infusion is rooted in a shared commitment to advancing access, quality and innovation in ambulatory infusion care,” said Ted Kramm, CEO of BioMatrix Infusion Pharmacy. “Together, we are better positioned to transform infusion care delivery and ensure that patients nationwide receive the highest standard of treatment.”
“We founded LUX to deliver clinical excellence in a setting of comfort and convenience. Proving this model in Alaska, while lowering costs for complex treatments, exceeded our expectations,” said Lisa Bruce, Co-Founder of LUX Infusion. “Partnering with BioMatrix strengthens our commitment and allows us to expand this model nationwide, raising the standard of outpatient infusion care with partners who share our vision and values.”
According to data in the LevinPro HC database, this transaction marks the 12th infusion services acquisition of 2025. Half of the infusion services deals this year have been announced by private equity firms and/or their portfolio companies. Other PE firms recently involved in the space include Seven Hills Capital, DFW Capital Partners (through Singlepoint Healthcare), Revelstoke Capital Partners, RF Investment Partners and InTandem Capital Partners (through Vivo Infusion). There were 17 infusion services deals announced in 2024.
